CHAMBERLAIN UNIVERSITY | COLLEGE OF NURSING | GRADUATE NURSING & ADVANCED PRACTICE
EDUCATION
NR568 / NR 568 FINAL EXAM (LATEST )
ADVANCED PHARMACOLOGY FOR THE ADULT-GERONTOLOGY PRIMARY CARE
NURSE PRACTITIONER
Comprehensive Final Examination with Verified Answers and Detailed Rationales
Aligned with the Chamberlain University NR 568 Course Syllabus - AACN Essentials of Master's Education in Nursing -
Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP) Pharmacology Competencies
TOTAL QUESTIONS STRUCTURE QUESTION STYLE COGNITIVE LEVELS
150 multiple-choice items 9 sections: 20 + 15 + 20 + 75% scenario-based clinical 20% recall - 50%
(A-D), one correct answer 15 + 20 + 15 + 15 + 15 + application; 25% direct application - 30% analysis
each 15 knowledge (clinical reasoning,
medication selection,
monitoring)
DIRECTIONS. Select the single best answer (A through D) for each of the 150 items. The correct answer is flagged with
[CORRECT] and stated beneath the options, followed by a rationale explaining why the keyed response is correct and why
the distractors are wrong, with reference to NR 568 curriculum objectives, AACN Essentials competencies, and advanced
pharmacology principles. Scenario items present adult-gerontology primary care encounters requiring medication selection,
side-effect management, monitoring design, or patient education; read the entire stem, including laboratory values and
comorbidities, before answering. Special inclusions are distributed throughout: twenty scenario-based clinical reasoning
items, twenty cardiovascular and endocrine pharmacology items (Sections 3 and 5), and fifteen special-population items
(Section 9).
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS | Questions 1 - 20
Q1. A nurse practitioner student asks for a precise definition of a drug's elimination half-life (t1/2).
Which statement by the student demonstrates correct understanding of this pharmacokinetic parameter?
A. The time required for the plasma concentration of a drug to decrease by 50 percent [CORRECT]
B. The time required for a drug to reach its peak plasma concentration after oral administration
C. The time required for 100 percent of the administered dose to be eliminated from the body
D. The time required for a drug to achieve its maximum therapeutic effect in the target tissue
Correct Answer: A
Rationale: Half-life is the time needed for plasma concentration to fall by 50 percent, and it governs dosing
interval, time to steady state, and duration of action. Peak concentration describes Tmax (option B), not
elimination; complete elimination requires roughly 5 half-lives, not one half-life (option C); and time to maximum
effect is a pharmacodynamic outcome, not the definition of t1/2 (option D). NR 568 module content emphasizes
mastering t1/2 because it drives every clinical dosing-interval decision the AGPCNP makes.
1
,NR568 / NR 568 FINAL EXAM (LATEST ) - ADVANCED PHARMACOLOGY FOR THE AGPCNP CHAMBERLAIN
Q2. A 58-year-old woman starts an oral medication whose half-life is 12 hours, taken every 12 hours.
She asks when the drug will reach steady state so she can judge its full effect. Approximately how long
will this take?
A. About 24 hours, or two half-lives
B. About 36 hours, or three half-lives
C. About 48 to 60 hours, or four to five half-lives [CORRECT]
D. Steady state is reached only with a loading dose and cannot be predicted from half-life
Correct Answer: C
Rationale: Steady state is achieved after approximately 4 to 5 half-lives of consistent dosing, so with a 12-hour
half-life the patient needs about 48 to 60 hours regardless of whether a loading dose is used; a loading dose only
shortens the time to therapeutic concentration, not to steady state. Options A and B underestimate the time, and
option D is incorrect because half-life directly predicts steady-state timing. This concept is a core NR 568
application objective and is essential for setting realistic patient expectations during medication education (AACN
Essential IX, population-focused pharmacotherapeutics).
Q3. A 34-year-old man with new-onset atrial fibrillation is started on a drug with a very long half-life
(amiodarone). The nurse practitioner prescribes a loading dose followed by a lower maintenance dose.
What is the primary pharmacokinetic rationale for this strategy?
A. A loading dose saturates renal tubular secretion so that maintenance doses are excreted more slowly
B. A loading dose reduces the risk of hypersensitivity reactions associated with chronic amiodarone
therapy
C. A loading dose rapidly fills the volume of distribution to achieve therapeutic plasma concentrations
without waiting for steady state [CORRECT]
D. A loading dose prevents the development of drug tolerance that would otherwise occur during
maintenance therapy
Correct Answer: C
Rationale: For drugs with long half-lives and large volumes of distribution, a loading dose (based on volume of
distribution and target concentration) rapidly achieves therapeutic levels instead of waiting 4 to 5 half-lives, which
for amiodarone could take weeks. Option A misstates renal saturation physiology, option B has no pharmacologic
basis, and option D confuses loading doses with tolerance prevention. Advanced pharmacology (NR 568,
dose-design unit) requires the AGPCNP to understand loading dose = target concentration x volume of
distribution / bioavailability when initiating long-half-life agents.
2
,NR568 / NR 568 FINAL EXAM (LATEST ) - ADVANCED PHARMACOLOGY FOR THE AGPCNP CHAMBERLAIN
Q4. A patient with stable angina takes sublingual nitroglycerin rather than an oral tablet. The nurse
practitioner explains that this route is chosen primarily because of which pharmacokinetic
phenomenon?
A. Ion trapping of nitroglycerin in the acidic gastric environment
B. Active transport of nitroglycerin across the intestinal mucosa, which is bypassed sublingually
C. Extensive first-pass hepatic metabolism that destroys most orally administered nitroglycerin
[CORRECT]
D. Enterogastric recycling that makes oral nitroglycerin levels rise and fall unpredictably
Correct Answer: C
Rationale: Nitroglycerin undergoes extensive first-pass metabolism by hepatic nitrate reductases, giving oral
bioavailability of only about 1 to 5 percent, so it is given sublingually to bypass the portal circulation and enter the
systemic circulation directly. Options A and D describe phenomena that do not apply to nitrate delivery, and
option B is incorrect because nitroglycerin crosses mucosa by passive diffusion. NR 568 links the first-pass effect
directly to route selection, a decision-making competency the AGPCNP applies with every prescription (AACN
Essential I, scientific underpinnings for practice).
Q5. A 72-year-old woman stabilized on warfarin is prescribed double-strength
sulfamethoxazole/trimethoprim for a urinary tract infection. Three days later her INR has risen sharply
from 2.4 to 5.8. Which pharmacokinetic mechanism best explains this interaction?
A. The antibiotic increases hepatic blood flow, raising the rate of warfarin metabolism
B. The antibiotic induces CYP3A4, converting warfarin to a more potent metabolite
C. Displacement of warfarin from plasma protein binding plus CYP2C9 inhibition transiently increases
active drug exposure [CORRECT]
D. The antibiotic reduces warfarin absorption by chelating it within the intestinal lumen
Correct Answer: C
Rationale: Warfarin is approximately 99 percent protein bound; highly bound coadministered drugs can displace
it and transiently raise the free (active) fraction, while trimethoprim-sulfamethoxazole also inhibits CYP2C9,
together producing a supratherapeutic INR. Option A is wrong because increased metabolism would lower the
INR, option B misidentifies the pathway (S-warfarin is cleared by CYP2C9), and option D would decrease, not
increase, anticoagulation. NR 568 teaches that protein-binding displacement matters most for
narrow-therapeutic-index, highly bound drugs, a high-priority safety concept for the AGPCNP.
Q6. Which group of medications requires routine therapeutic drug monitoring (TDM) because its
members share a narrow therapeutic index?
A. Amlodipine, lisinopril, and hydrochlorothiazide
B. Metformin, sitagliptin, and empagliflozin
C. Digoxin, phenytoin, lithium, and warfarin [CORRECT]
D. Atorvastatin, ezetimibe, and alirocumab
Correct Answer: C
Rationale: Digoxin, phenytoin, lithium, and warfarin are classic narrow-therapeutic-index drugs in which small
changes in level produce toxicity or therapeutic failure, so serum levels or surrogate markers (INR) are monitored
routinely. The agents in options A, B, and D have wide therapeutic margins and are monitored clinically rather
than by serum levels. NR 568 course objectives list therapeutic index and TDM selection as core content, and
AGPCNP competency standards require knowing which drugs justify level-based monitoring and when to order it.
3
, NR568 / NR 568 FINAL EXAM (LATEST ) - ADVANCED PHARMACOLOGY FOR THE AGPCNP CHAMBERLAIN
Q7. A long-term smoker with asthma is stabilized on oral theophylline. After successful smoking
cessation, the patient reports tremor and palpitations. Which mechanism best explains this presentation?
A. Loss of smoking-induced CYP1A2 induction slowed theophylline clearance, increasing plasma
levels [CORRECT]
B. Smoking cessation enhanced theophylline receptor sensitivity at the adenosine receptor
C. Nicotine replacement therapy competitively inhibits theophylline metabolism
D. Stopping smoking reduced renal tubular secretion of theophylline
Correct Answer: A
Rationale: Polycyclic aromatic hydrocarbons in tobacco smoke induce CYP1A2; when smoking stops, induction
fades over 1 to 2 weeks and theophylline clearance falls, producing toxicity (tremor, palpitations, nausea), so the
dose should be reduced and levels rechecked. Option B is receptor-sensitivity reasoning that does not apply, option
C is incorrect because nicotine itself does not inhibit CYP1A2, and option D is wrong because theophylline is
cleared hepatically. This is a classic CYP-induction analysis item in NR 568 and reflects AGPCNP competency in
recognizing environmental determinants of drug response.
Q8. A 79-year-old woman (weight 58 kg, serum creatinine 1.4 mg/dL, estimated creatinine clearance
about 28 mL/min) has new postherpetic neuralgia. Which prescribing decision best reflects correct renal
pharmacokinetic principles?
A. Prescribe reduced-dose, extended-interval gabapentin dosing based on creatinine clearance with
slow titration [CORRECT]
B. Prescribe full-dose gabapentin 300 mg three times daily and titrate rapidly upward
C. Avoid gabapentin entirely because it is absolutely contraindicated when creatinine clearance is
below 45 mL/min
D. Prescribe full-dose gabapentin because age does not alter the pharmacokinetics of renally eliminated
drugs
Correct Answer: A
Rationale: Gabapentin is eliminated almost entirely unchanged by the kidney, so doses must be adjusted to
creatinine clearance (about 200 to 700 mg/day total at this clearance level) with slow titration to limit neurotoxicity
such as somnolence and ataxia. Option B risks accumulation in renal impairment, option C states an incorrect
absolute contraindication, and option D ignores the fundamental relationship between renal function and drug
elimination. NR 568 geriatric pharmacokinetics content and AGPCNP competencies require estimating renal
function and individualizing dosing in older adults before initiating renally cleared drugs.
4
EDUCATION
NR568 / NR 568 FINAL EXAM (LATEST )
ADVANCED PHARMACOLOGY FOR THE ADULT-GERONTOLOGY PRIMARY CARE
NURSE PRACTITIONER
Comprehensive Final Examination with Verified Answers and Detailed Rationales
Aligned with the Chamberlain University NR 568 Course Syllabus - AACN Essentials of Master's Education in Nursing -
Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP) Pharmacology Competencies
TOTAL QUESTIONS STRUCTURE QUESTION STYLE COGNITIVE LEVELS
150 multiple-choice items 9 sections: 20 + 15 + 20 + 75% scenario-based clinical 20% recall - 50%
(A-D), one correct answer 15 + 20 + 15 + 15 + 15 + application; 25% direct application - 30% analysis
each 15 knowledge (clinical reasoning,
medication selection,
monitoring)
DIRECTIONS. Select the single best answer (A through D) for each of the 150 items. The correct answer is flagged with
[CORRECT] and stated beneath the options, followed by a rationale explaining why the keyed response is correct and why
the distractors are wrong, with reference to NR 568 curriculum objectives, AACN Essentials competencies, and advanced
pharmacology principles. Scenario items present adult-gerontology primary care encounters requiring medication selection,
side-effect management, monitoring design, or patient education; read the entire stem, including laboratory values and
comorbidities, before answering. Special inclusions are distributed throughout: twenty scenario-based clinical reasoning
items, twenty cardiovascular and endocrine pharmacology items (Sections 3 and 5), and fifteen special-population items
(Section 9).
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS | Questions 1 - 20
Q1. A nurse practitioner student asks for a precise definition of a drug's elimination half-life (t1/2).
Which statement by the student demonstrates correct understanding of this pharmacokinetic parameter?
A. The time required for the plasma concentration of a drug to decrease by 50 percent [CORRECT]
B. The time required for a drug to reach its peak plasma concentration after oral administration
C. The time required for 100 percent of the administered dose to be eliminated from the body
D. The time required for a drug to achieve its maximum therapeutic effect in the target tissue
Correct Answer: A
Rationale: Half-life is the time needed for plasma concentration to fall by 50 percent, and it governs dosing
interval, time to steady state, and duration of action. Peak concentration describes Tmax (option B), not
elimination; complete elimination requires roughly 5 half-lives, not one half-life (option C); and time to maximum
effect is a pharmacodynamic outcome, not the definition of t1/2 (option D). NR 568 module content emphasizes
mastering t1/2 because it drives every clinical dosing-interval decision the AGPCNP makes.
1
,NR568 / NR 568 FINAL EXAM (LATEST ) - ADVANCED PHARMACOLOGY FOR THE AGPCNP CHAMBERLAIN
Q2. A 58-year-old woman starts an oral medication whose half-life is 12 hours, taken every 12 hours.
She asks when the drug will reach steady state so she can judge its full effect. Approximately how long
will this take?
A. About 24 hours, or two half-lives
B. About 36 hours, or three half-lives
C. About 48 to 60 hours, or four to five half-lives [CORRECT]
D. Steady state is reached only with a loading dose and cannot be predicted from half-life
Correct Answer: C
Rationale: Steady state is achieved after approximately 4 to 5 half-lives of consistent dosing, so with a 12-hour
half-life the patient needs about 48 to 60 hours regardless of whether a loading dose is used; a loading dose only
shortens the time to therapeutic concentration, not to steady state. Options A and B underestimate the time, and
option D is incorrect because half-life directly predicts steady-state timing. This concept is a core NR 568
application objective and is essential for setting realistic patient expectations during medication education (AACN
Essential IX, population-focused pharmacotherapeutics).
Q3. A 34-year-old man with new-onset atrial fibrillation is started on a drug with a very long half-life
(amiodarone). The nurse practitioner prescribes a loading dose followed by a lower maintenance dose.
What is the primary pharmacokinetic rationale for this strategy?
A. A loading dose saturates renal tubular secretion so that maintenance doses are excreted more slowly
B. A loading dose reduces the risk of hypersensitivity reactions associated with chronic amiodarone
therapy
C. A loading dose rapidly fills the volume of distribution to achieve therapeutic plasma concentrations
without waiting for steady state [CORRECT]
D. A loading dose prevents the development of drug tolerance that would otherwise occur during
maintenance therapy
Correct Answer: C
Rationale: For drugs with long half-lives and large volumes of distribution, a loading dose (based on volume of
distribution and target concentration) rapidly achieves therapeutic levels instead of waiting 4 to 5 half-lives, which
for amiodarone could take weeks. Option A misstates renal saturation physiology, option B has no pharmacologic
basis, and option D confuses loading doses with tolerance prevention. Advanced pharmacology (NR 568,
dose-design unit) requires the AGPCNP to understand loading dose = target concentration x volume of
distribution / bioavailability when initiating long-half-life agents.
2
,NR568 / NR 568 FINAL EXAM (LATEST ) - ADVANCED PHARMACOLOGY FOR THE AGPCNP CHAMBERLAIN
Q4. A patient with stable angina takes sublingual nitroglycerin rather than an oral tablet. The nurse
practitioner explains that this route is chosen primarily because of which pharmacokinetic
phenomenon?
A. Ion trapping of nitroglycerin in the acidic gastric environment
B. Active transport of nitroglycerin across the intestinal mucosa, which is bypassed sublingually
C. Extensive first-pass hepatic metabolism that destroys most orally administered nitroglycerin
[CORRECT]
D. Enterogastric recycling that makes oral nitroglycerin levels rise and fall unpredictably
Correct Answer: C
Rationale: Nitroglycerin undergoes extensive first-pass metabolism by hepatic nitrate reductases, giving oral
bioavailability of only about 1 to 5 percent, so it is given sublingually to bypass the portal circulation and enter the
systemic circulation directly. Options A and D describe phenomena that do not apply to nitrate delivery, and
option B is incorrect because nitroglycerin crosses mucosa by passive diffusion. NR 568 links the first-pass effect
directly to route selection, a decision-making competency the AGPCNP applies with every prescription (AACN
Essential I, scientific underpinnings for practice).
Q5. A 72-year-old woman stabilized on warfarin is prescribed double-strength
sulfamethoxazole/trimethoprim for a urinary tract infection. Three days later her INR has risen sharply
from 2.4 to 5.8. Which pharmacokinetic mechanism best explains this interaction?
A. The antibiotic increases hepatic blood flow, raising the rate of warfarin metabolism
B. The antibiotic induces CYP3A4, converting warfarin to a more potent metabolite
C. Displacement of warfarin from plasma protein binding plus CYP2C9 inhibition transiently increases
active drug exposure [CORRECT]
D. The antibiotic reduces warfarin absorption by chelating it within the intestinal lumen
Correct Answer: C
Rationale: Warfarin is approximately 99 percent protein bound; highly bound coadministered drugs can displace
it and transiently raise the free (active) fraction, while trimethoprim-sulfamethoxazole also inhibits CYP2C9,
together producing a supratherapeutic INR. Option A is wrong because increased metabolism would lower the
INR, option B misidentifies the pathway (S-warfarin is cleared by CYP2C9), and option D would decrease, not
increase, anticoagulation. NR 568 teaches that protein-binding displacement matters most for
narrow-therapeutic-index, highly bound drugs, a high-priority safety concept for the AGPCNP.
Q6. Which group of medications requires routine therapeutic drug monitoring (TDM) because its
members share a narrow therapeutic index?
A. Amlodipine, lisinopril, and hydrochlorothiazide
B. Metformin, sitagliptin, and empagliflozin
C. Digoxin, phenytoin, lithium, and warfarin [CORRECT]
D. Atorvastatin, ezetimibe, and alirocumab
Correct Answer: C
Rationale: Digoxin, phenytoin, lithium, and warfarin are classic narrow-therapeutic-index drugs in which small
changes in level produce toxicity or therapeutic failure, so serum levels or surrogate markers (INR) are monitored
routinely. The agents in options A, B, and D have wide therapeutic margins and are monitored clinically rather
than by serum levels. NR 568 course objectives list therapeutic index and TDM selection as core content, and
AGPCNP competency standards require knowing which drugs justify level-based monitoring and when to order it.
3
, NR568 / NR 568 FINAL EXAM (LATEST ) - ADVANCED PHARMACOLOGY FOR THE AGPCNP CHAMBERLAIN
Q7. A long-term smoker with asthma is stabilized on oral theophylline. After successful smoking
cessation, the patient reports tremor and palpitations. Which mechanism best explains this presentation?
A. Loss of smoking-induced CYP1A2 induction slowed theophylline clearance, increasing plasma
levels [CORRECT]
B. Smoking cessation enhanced theophylline receptor sensitivity at the adenosine receptor
C. Nicotine replacement therapy competitively inhibits theophylline metabolism
D. Stopping smoking reduced renal tubular secretion of theophylline
Correct Answer: A
Rationale: Polycyclic aromatic hydrocarbons in tobacco smoke induce CYP1A2; when smoking stops, induction
fades over 1 to 2 weeks and theophylline clearance falls, producing toxicity (tremor, palpitations, nausea), so the
dose should be reduced and levels rechecked. Option B is receptor-sensitivity reasoning that does not apply, option
C is incorrect because nicotine itself does not inhibit CYP1A2, and option D is wrong because theophylline is
cleared hepatically. This is a classic CYP-induction analysis item in NR 568 and reflects AGPCNP competency in
recognizing environmental determinants of drug response.
Q8. A 79-year-old woman (weight 58 kg, serum creatinine 1.4 mg/dL, estimated creatinine clearance
about 28 mL/min) has new postherpetic neuralgia. Which prescribing decision best reflects correct renal
pharmacokinetic principles?
A. Prescribe reduced-dose, extended-interval gabapentin dosing based on creatinine clearance with
slow titration [CORRECT]
B. Prescribe full-dose gabapentin 300 mg three times daily and titrate rapidly upward
C. Avoid gabapentin entirely because it is absolutely contraindicated when creatinine clearance is
below 45 mL/min
D. Prescribe full-dose gabapentin because age does not alter the pharmacokinetics of renally eliminated
drugs
Correct Answer: A
Rationale: Gabapentin is eliminated almost entirely unchanged by the kidney, so doses must be adjusted to
creatinine clearance (about 200 to 700 mg/day total at this clearance level) with slow titration to limit neurotoxicity
such as somnolence and ataxia. Option B risks accumulation in renal impairment, option C states an incorrect
absolute contraindication, and option D ignores the fundamental relationship between renal function and drug
elimination. NR 568 geriatric pharmacokinetics content and AGPCNP competencies require estimating renal
function and individualizing dosing in older adults before initiating renally cleared drugs.
4
